Literature DB >> 21134656

Elective regional nodal irradiation in patients with early-stage breast cancer.

Liyi Xie1, Daniel S Higginson, Lawrence B Marks.   

Abstract

Elective regional lymph nodal irradiation is controversial in patients with early stage breast cancer. Under the "Halstedian" model of tumor progression, elective nodal irradiation would be expected to provide some gain in both regional control and survival. Nevertheless, the data are inconclusive. When the axillary nodes are positive, there is uncertainty regarding the utility of elective irradiation of the supraclavicular and internal mammary areas. Similarly, in patients with a clinically negative axilla, the role of elective irradiation of the axilla and other nodal sites is also controversial. This article reviews data from trials that address the utility of elective regional nodal treatment, with regard to both tumor control (local control and survival) and morbidity. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2011        PMID: 21134656     DOI: 10.1016/j.semradonc.2010.08.006

Source DB:  PubMed          Journal:  Semin Radiat Oncol        ISSN: 1053-4296            Impact factor:   5.934


  9 in total

1.  Risk Factors for Arm Lymphedema in a Cohort of Breast Cancer Patients Followed up for 10 Years.

Authors:  René Aloisio da Costa Vieira; Allini Mafra da Costa; Josue Lopes de Souza; Rafael Richieri Coelho; Cleyton Zanardo de Oliveira; Almir José Sarri; Renato José Affonso Junior; Gustavo Zucca-Matthes
Journal:  Breast Care (Basel)       Date:  2015-12-14       Impact factor: 2.860

Review 2.  Consensus on the regional lymph nodes irradiation in breast cancer.

Authors:  E Bayo; I Herruzo; M Arenas; M Algara
Journal:  Clin Transl Oncol       Date:  2013-03-22       Impact factor: 3.405

3.  Unplanned irradiation of internal mammary lymph nodes in breast cancer.

Authors:  Gul Kanyilmaz; Meryem Aktan; Mehmet Koc; Hikmettin Demir; Lütfi Saltuk Demir
Journal:  Radiol Med       Date:  2017-03-03       Impact factor: 3.469

Review 4.  Internal mammary lymph node metastasis in breast cancer patients based on anatomical imaging and functional imaging.

Authors:  Wei Wang; Pengfei Qiu; Jianbin Li
Journal:  Breast Cancer       Date:  2022-06-24       Impact factor: 3.307

Review 5.  Management of Axilla in 2015 in Indian Scenario.

Authors:  D K Vijaykumar; M Arunlal
Journal:  Indian J Surg Oncol       Date:  2015-10-30

6.  Prognostic Impact of Elective Supraclavicular Nodal Irradiation for Patients with N1 Breast Cancer after Lumpectomy and Anthracycline Plus Taxane-Based Chemotherapy (KROG 1418): A Multicenter Case-Controlled Study.

Authors:  Haeyoung Kim; Won Park; Jeong Il Yu; Doo Ho Choi; Seung Jae Huh; Yeon-Joo Kim; Eun Sook Lee; Keun Seok Lee; Han-Sung Kang; In Hae Park; Kyung Hwan Shin; Chan Woo Wee; Kyubo Kim; Kyung Ran Park; Yong Bae Kim; Sung Ja Ahn; Jong Hoon Lee; Jin Hee Kim; Mison Chun; Hyung-Sik Lee; Jung Soo Kim; Jihye Cha
Journal:  Cancer Res Treat       Date:  2017-01-04       Impact factor: 4.679

7.  Postmastectomy radiotherapy using three different techniques: a retrospective evaluation of the incidental dose distribution in the internal mammary nodes.

Authors:  Wei Wang; Yingjie Zhang; Min Xu; Qian Shao; Tao Sun; Ting Yu; Xijun Liu; Jianbin Li
Journal:  Cancer Manag Res       Date:  2019-01-30       Impact factor: 3.989

8.  Factors Influencing the Incidental Dose Distribution in Internal Mammary Nodes: A Comparative Study.

Authors:  Wei Wang; Jinzhi Wang; Pengfei Qiu; Tao Sun; Yingjie Zhang; Qian Shao; Min Xu; Xijun Liu; Jianbin Li
Journal:  Front Oncol       Date:  2020-04-09       Impact factor: 6.244

9.  OPTimizing Irradiation through Molecular Assessment of Lymph node (OPTIMAL): a randomized open label trial.

Authors:  Manuel Algara López; Elvira Rodríguez García; Inmaculada Beato Tortajada; Francisco José Martínez Arcelus; Juan Salinas Ramos; José Reyes Rodríguez Garrido; Xavier Sanz Latiesas; Ana Soler Rodríguez; Germán Juan Rijo; Amanda Flaquer García
Journal:  Radiat Oncol       Date:  2020-10-02       Impact factor: 3.481

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.